BURLINGAME, Calif.--(BUSINESS WIRE)--March 22, 2006--VistaGen Therapeutics, Inc., a biopharmaceutical company applying leading embryonic stem cell technology to discover and develop novel treatments for central nervous system disorders, diabetes and cardiovascular disease, and Cato BioVentures, the venture capital affiliate of Cato Research Ltd., a global contract research organization, announced today the signing of a strategic business development agreement. The agreement grants VistaGen exclusive rights of first negotiation to all CNS product opportunities identified or acquired by Cato BioVentures and Cato Research.
